Dare Bioscience (DARE) Change in Cash (2013 - 2025)
Dare Bioscience's (DARE) quarterly Change in Cash came in at $1.6 million in Q4 2025, down 63.36% YoY from $4.5 million in Q4 2024, and down 90.93% on a QoQ basis from $18.0 million in Q3 2025.
Dare Bioscience (DARE) Change in Cash (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Change in Cash data on file, last reported at $1.6 million in Q4 2025.
- Quarterly Change in Cash fell 63.36% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.0 million (up 73.76% YoY) and the FY2025 annual result came in at $9.0 million, up 73.76% from the prior year.
- Change in Cash eased to $1.6 million in Q4 2025, from $18.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $36.5 million in Q3 2021 to a low of -$14.8 million in Q1 2023.
- A 5-year average of $1.0 million and a median of -$1.4 million in 2023 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2021 — Change in Cash soared 85601.28% — and 2024, when it sank 1016.71%.
- Tracing DARE's Change in Cash over 5 years: stood at $6.1 million in 2021, then sank by 193.72% to -$5.7 million in 2022, then surged by 40.24% to -$3.4 million in 2023, then surged by 230.63% to $4.5 million in 2024, then tumbled by 63.36% to $1.6 million in 2025.
- The last three Change in Cash figures came in at $1.6 million (Q4 2025), $18.0 million (Q3 2025), and -$5.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 18.04 Mn |
| Jun 30, 2025 | -5.29 Mn |
| Mar 31, 2025 | -5.37 Mn |
| Dec 31, 2024 | 4.47 Mn |
| Sep 30, 2024 | -5.18 Mn |
| Jun 30, 2024 | 12.75 Mn |
| Mar 31, 2024 | -6.85 Mn |
| Dec 31, 2023 | -3.42 Mn |
| Sep 30, 2023 | 565,323.00 |
| Jun 30, 2023 | -6.17 Mn |
| Mar 31, 2023 | -14.84 Mn |
| Dec 31, 2022 | -5.72 Mn |
| Sep 30, 2022 | 8.32 Mn |
| Jun 30, 2022 | -7.25 Mn |
| Mar 31, 2022 | -12.36 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 36.46 Mn |
| Jun 30, 2021 | 1.45 Mn |
| Mar 31, 2021 | 2.99 Mn |